Zobrazeno 1 - 10
of 10
pro vyhledávání: '"J. Chris Brady"'
Autor:
Andrew B. Nixon, Michael J. Birrer, Robert A. Burger, Wei Deng, Matthew Boente, Keiichi Fujiwara, Jamie N. Bakkum-Gamez, Heidi Gray, David M. O'Malley, Krishnansu S. Tewari, Robert S. Mannel, Herbert I. Hurwitz, Heather A. Lankes, J. Chris Brady, Mark D. Starr, Yingmiao Liu, Alexander B. Sibley, David Tritchler, Kouros Owzar, Kirsten Bell Burdett, Angeles Alvarez Secord
The medians and ranges for all analytes at baseline.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfdb15a333993a7d4bcfda6d7564e9e2
https://doi.org/10.1158/1078-0432.22473075
https://doi.org/10.1158/1078-0432.22473075
Autor:
Andrew B. Nixon, Michael J. Birrer, Robert A. Burger, Wei Deng, Matthew Boente, Keiichi Fujiwara, Jamie N. Bakkum-Gamez, Heidi Gray, David M. O'Malley, Krishnansu S. Tewari, Robert S. Mannel, Herbert I. Hurwitz, Heather A. Lankes, J. Chris Brady, Mark D. Starr, Yingmiao Liu, Alexander B. Sibley, David Tritchler, Kouros Owzar, Kirsten Bell Burdett, Angeles Alvarez Secord
Purpose:GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c46078192db3ae0cddc44cbfc81d043
https://doi.org/10.1158/1078-0432.c.6528411.v1
https://doi.org/10.1158/1078-0432.c.6528411.v1
Autor:
Andrew B. Nixon, Michael J. Birrer, Robert A. Burger, Wei Deng, Matthew Boente, Keiichi Fujiwara, Jamie N. Bakkum-Gamez, Heidi Gray, David M. O'Malley, Krishnansu S. Tewari, Robert S. Mannel, Herbert I. Hurwitz, Heather A. Lankes, J. Chris Brady, Mark D. Starr, Yingmiao Liu, Alexander B. Sibley, David Tritchler, Kouros Owzar, Kirsten Bell Burdett, Angeles Alvarez Secord
Relationship between covariates and IL6.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266a08394301daee8fdb58e7861c5bca
https://doi.org/10.1158/1078-0432.22473087.v1
https://doi.org/10.1158/1078-0432.22473087.v1
Autor:
Andrew B. Nixon, Michael J. Birrer, Robert A. Burger, Wei Deng, Matthew Boente, Keiichi Fujiwara, Jamie N. Bakkum-Gamez, Heidi Gray, David M. O'Malley, Krishnansu S. Tewari, Robert S. Mannel, Herbert I. Hurwitz, Heather A. Lankes, J. Chris Brady, Mark D. Starr, Yingmiao Liu, Alexander B. Sibley, David Tritchler, Kouros Owzar, Kirsten Bell Burdett, Angeles Alvarez Secord
Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13a83f6259c9f2a856f3b2d3b4515392
https://doi.org/10.1158/1078-0432.22473081.v1
https://doi.org/10.1158/1078-0432.22473081.v1
Autor:
Andrew B. Nixon, Michael J. Birrer, Robert A. Burger, Wei Deng, Matthew Boente, Keiichi Fujiwara, Jamie N. Bakkum-Gamez, Heidi Gray, David M. O'Malley, Krishnansu S. Tewari, Robert S. Mannel, Herbert I. Hurwitz, Heather A. Lankes, J. Chris Brady, Mark D. Starr, Yingmiao Liu, Alexander B. Sibley, David Tritchler, Kouros Owzar, Kirsten Bell Burdett, Angeles Alvarez Secord
3-way interaction analyses between outcome, treatment, and markers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d75ad55214ccd31b624b3f412800b92
https://doi.org/10.1158/1078-0432.22473084.v1
https://doi.org/10.1158/1078-0432.22473084.v1
Autor:
Angeles Alvarez Secord, Michael McCollum, Mark D. Starr, Robert Squatrito, Linda R. Duska, Gloria Broadwater, Brittany A. Davidson, J. Chris Brady, Laura J. Havrilesky, Andrew B. Nixon, Anne C. Gabel
Publikováno v:
Gynecologic Oncology. 153:555-561
Bevacizumab provides benefit in epithelial ovarian cancer (EOC), yet resistance to bevacizumab often occurs. We determined if nintedanib, a tyrosine kinase inhibitor of VEGF, FGF, and PDGF receptors has antitumor activity in bevacizumab-resistant rec
Autor:
Heather A. Lankes, Michael J. Birrer, Robert A. Burger, Yingmiao Liu, David M. O'Malley, Matthew P. Boente, Wei Deng, Andrew B. Nixon, Jamie N. Bakkum-Gamez, J. Chris Brady, Kouros Owzar, Krishnansu S. Tewari, Kirsten Bell Burdett, David Tritchler, Mark D. Starr, Angeles Alvarez Secord, Alexander B. Sibley, Herbert Hurwitz, Keiichi Fujiwara, Robert S. Mannel, Heidi J. Gray
Publikováno v:
Clin Cancer Res
Purpose: GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demon
Autor:
Ace J. Hatch, Alexander B. Sibley, J. Chris Brady, Herbert Pang, Chen Jiang, Kouros Owzar, Daniel L Bowers, Mark D. Starr, Herbert Hurwitz, Federico Innocenti, Alan P. Venook, Donna Niedzwiecki, Jingquan Jia, Andrew B. Nixon
Publikováno v:
Cancer Medicine
Circulating protein markers were assessed in patients with colorectal cancer (CRC) treated with cetuximab in CALGB 80203 to identify prognostic and predictive biomarkers. Patients with locally advanced or metastatic CRC received FOLFOX or FOLFIRI che
Autor:
Dominic T. Moore, Andrew B. Nixon, Yingmiao Liu, J. Chris Brady, Bert H. O'Neil, Kirsten Bell Burdett, Kelli Hammond, Hanna K. Sanoff, Mark D. Starr, Federico Innocenti, Ace J. Hatch, Anastasia Ivanova, Michael Sangmin Lee, Kouros Owzar
Publikováno v:
Journal of Clinical Oncology. 37:587-587
587 Background: The LCCC1029 trial demonstrated that addition of the multitargeted kinase inhibitor regorafenib (Rego) to FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts) modestly prolonged progression-free survival (PFS). In this prepla
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.